• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Cohen Independent Research Group Initiates Coverage of Power3 Medical Products

Posted on: Tuesday, 18 July 2006, 09:00 CDT

Power3 Medical Products, Inc. (OTC: PWRM), a leading proteomics company that develops and commercializes early detection diagnostic tests for breast cancer and neurodegenerative diseases, announced today that the Cohen Independent Research Group has initiated coverage of its stock.

Based in San Rafael, California, Cohen Research (www.CohenResearch.com) was founded by D. Paul Cohen, and has a strong record of working with emerging growth companies in the U.S. that do not have current analyst coverage, but who, according to Mr. Cohen's proprietary valuation techniques, are "undervalued and destined for long-term growth and success."

Mr. Cohen's background includes extensive experience as an analyst, and having co-founded West Coast offices of Bear Stearns and CBWL Hayden Stone/American Express (became Shearson Lehman Bros). His company's philosophy is that, among the approximately 4,500 public companies in the U.S. that currently do not have analyst coverage, "there are some hidden gems that the investment public should be aware of . . . including Power3 Medical Products," he said.

Power3 Medical Products, Inc.'s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and treatment of disease, and it has identified protein biomarkers, drug targets, and diagnostic tests that are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. Power3 operates a state-of-the-art proteomics laboratory in an area known as The Woodlands, near Houston, Texas.

About Power3 Medical Products

Power3 Medical Products, Inc. (PWRM.PK, www.Power3Medical.com), is a leading proteomics company engaged in the commercialization of protein biomarkers, pathways, and mechanisms of diseases, through the development of diagnostic tests and drug targets for cancer and neurodegenerative diseases. Power3's patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and treatment of disease, and its identified protein biomarkers, drug targets, and diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. Power3 operates a state-of-the-art proteomics laboratory in The Woodlands (Houston), Texas.

This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement.

Source: Business Wire

More News in this Category